Methods for inhibiting angiogenesis
AssigneeUniversity of Puerto Rico
InventorsDipak K. Banerjee, Juan A. Martinez
Life of this patent
Estimating the term…
Abstract
A method for inhibiting angiogenesis, including: administering a nucleoside, such as tunicamycin, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment. A method for inhibiting angiogenesis, including: administering a nucleoside, which comprises glucosamine, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment; wherein the nucleoside is administered for a period of time, subsequently the administration of the nucleoside is suspended for a period of time of at least about 1 week, and subsequently the administration of the nucleoside is resumed.
Claims92
A method for inhibiting angiogenesis, comprising:
- administering a nucleoside in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering a nucleoside, which comprises glucosamine, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment;
- wherein the nucleoside is administered for a period of time, subsequently the administration of the nucleoside is suspended for a period of time of at least about 1 week, and subsequently the administration of the nucleoside is resumed.
A method for inhibiting angiogenesis, comprising:
- administering a nucleoside in an amount effective to inhibit angiogenesis, to a patient in need of such treatment;
- wherein the nucleoside is represented by the following formula (I):
- 4
- where R may be:
- (CH3)2—CH—(CH2)n—CH═CH—(CO)—
- where:
- n may be 1-12
- α β unsaturated may be trans or cis;
- CH3—(CH2)w—CH═CH—(CO)—
- where:
- w may be 1-12
- α β unsaturated may be trans or cis;
- CxH2x+1—CH═CH—(CO)—
- where:
- x may be 1-30
- α β unsaturated may be trans or cis;
- (CH3)2—CH—(CH2)y—(CO)—
- where:
- y may be 1-12
- α β unsaturated may be trans or cis;
- or
- CH3—(CH2)z—(CO)—
- where:
- z maybe 1-12
- α β unsaturated may be trans or cis;
- wherein the nucleoside is administered for a period of time, subsequently the administration of the nucleoside is suspended for a period of time of at least about 1 week, and subsequently the administration of the nucleoside is resumed.
A method for inhibiting angiogenesis, comprising:
- administering tunicamycin in an amount effective to inhibit angiogenesis, to a patient in need of such treatment;
- wherein the tunicamycin is administered for a period of about 1 week to 6 months at a daily dosage of about 5 to 20 mg/kg of body weight, subsequently the administration of the tunicamycin is suspended for a period of about 1 week to 6 months, and subsequently the tunicamycin is administered for a period of about 1 week to 6 months at a daily dosage of about 5 to 20 mg/kg of body weight.
A method for inhibiting angiogenesis, comprising:
- administering an N-glycosylation inhibitor, which is not amphomycin, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering an agent which induces ER stress in capillary endothelial cells in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering an agent, which induces unfolded protein response, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering an agent which inhibits the dolichol pathway in an amount effective to inhibit angiogenesis, to a patient in need of such treatment, wherein the agent is not amphomycin.
A method for inhibiting angiogenesis, comprising:
- administering a Glc3Man9GlcNAc2-PP-Dol biosynthesis inhibitor, which is not amphomycin, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering GlcNAc-1P transferase inhibitor in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering an agent which reduces Dol-P-Man synthase activity in vivo in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering a non-peptide, which arrests the cell cycle of capillary endothelial cells in G1 phase, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering a non-peptide, which induces apoptosis in capillary endothelial cells, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- inducing accumulation of immunopositive Factor VIII:C in capillary endothelial cells to inhibit angiogenesis in a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering an agent, which inhibits the dolichol pathway, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment, wherein the agent is cell permeable.
A method for inhibiting angiogenesis, comprising:
- administering a Glc3Man9GlcNAc2-PP-Dol biosynthesis inhibitor, which is cell permeable, in an amount effective to inhibit angiogenesis, to a patient in need of such treatment.
A method for inhibiting angiogenesis, comprising:
- administering an agent which is cell permeable in an amount effective to inhibit angiogenesis, to a patient in need of such treatment to induce apoptosis in capillary endothelial cells.
A method for inhibiting angiogenesis, comprising:
- administering a cell permeable agent in an amount effective to inhibit angiogenesis, to a patient in need of such treatment to reduce intratumoral microvascular density.
Dependencies are inferred from the claim text.